ARE vs ONCO vs CTRE vs CRVS

For growth investors, CareTrust REIT, Inc.

(CTRE) is the stronger pick with 108. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). CareTrust REIT, Inc. (CTRE) offers the better valuation at 25. 2x trailing P/E (28. 0x forward), making it the more compelling value choice. Analysts rate CareTrust REIT, Inc. (CTRE) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, CareTrust REIT, Inc.

is actually cheaper at 28. 0x.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +401. 4%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: CTRE returned +280. 4% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CareTrust REIT, Inc.

(CTRE) is the lower-risk stock at 0. 20β versus Corvus Pharmaceuticals, Inc. 's 1. 57β — meaning CRVS is approximately 693% more volatile than CTRE relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 67% for Alexandria Real Estate Equities, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), CareTrust REIT, Inc.

(CTRE) is pulling ahead at 108. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to -568. 9% for Alexandria Real Estate Equities, Inc.. Over a 3-year CAGR, CTRE leads at 36. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

CareTrust REIT, Inc.

(CTRE) is the more profitable company, earning 67. 3% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 67. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTRE leads at 67. 2% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — ONCO leads at 77. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CareTrust REIT, Inc.

(CTRE) trades at 28. 0x forward P/E versus 61. 0x for Alexandria Real Estate Equities, Inc. — 33. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRVS: 127. 3% to $33. 17.

In this comparison, ONCO (30.

9% yield), ARE (11. 7% yield), CTRE (3. 2% yield) pay a dividend. CRVS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CareTrust REIT, Inc.

(CTRE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 20), 3. 2% yield, +280. 4% 10Y return). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTRE: +280. 4%, CRVS: +24. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ARE (Real Estate) and ONCO (Healthcare) and CTRE (Real Estate) and CRVS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ARE is a small-cap income-oriented stock; ONCO is a small-cap income-oriented stock; CTRE is a small-cap high-growth stock; CRVS is a small-cap quality compounder stock. ARE, ONCO, CTRE pay a dividend while CRVS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.